Bluebird Bio Inc. (BLUE) Given a $95.00 Price Target at Piper Jaffray Cos.
Bluebird Bio Inc. (NASDAQ:BLUE) has been assigned a $95.00 price target by Piper Jaffray Cos. in a report issued on Thursday. The firm currently has a a “buy” rating on the stock. Piper Jaffray Cos.’s target price would suggest a potential upside of 44.93% from the stock’s previous close.
BLUE has been the subject of a number of other research reports. Jefferies Group reaffirmed a “buy” rating and issued a $80.00 target price on shares of Bluebird Bio in a research report on Friday, September 23rd. Zacks Investment Research downgraded shares of Bluebird Bio from a “hold” rating to a “sell” rating in a research report on Wednesday, October 5th. Maxim Group set a $85.00 price objective on shares of Bluebird Bio and gave the company a “buy” rating in a research report on Thursday, September 22nd. Cowen and Company reissued an “outperform” rating on shares of Bluebird Bio in a research report on Friday, September 9th. Finally, Vetr downgraded shares of Bluebird Bio from a “buy” rating to a “hold” rating and set a $44.44 price objective for the company. in a research report on Monday, July 4th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $90.25.
Bluebird Bio (NASDAQ:BLUE) traded up 0.23% during mid-day trading on Thursday, reaching $65.70. 1,197,508 shares of the company were exchanged. Bluebird Bio has a 12-month low of $35.37 and a 12-month high of $99.70. The stock’s market capitalization is $2.44 billion. The company’s 50 day moving average price is $63.09 and its 200-day moving average price is $50.71.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/13/bluebird-bio-inc-blue-given-a-95-00-price-target-at-piper-jaffray-cos.html
Bluebird Bio (NASDAQ:BLUE) last released its earnings results on Wednesday, August 3rd. The company reported ($1.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.44) by $0.15. The business earned $1.55 million during the quarter, compared to the consensus estimate of $2.01 million. Bluebird Bio had a negative net margin of 3,512.13% and a negative return on equity of 24.85%. The firm’s revenue for the quarter was down 68.6% on a year-over-year basis. During the same period last year, the business posted ($1.57) EPS. On average, equities research analysts forecast that Bluebird Bio will post ($6.19) earnings per share for the current fiscal year.
In other news, insider Eric Sullivan sold 2,807 shares of the business’s stock in a transaction that occurred on Wednesday, July 20th. The shares were sold at an average price of $45.04, for a total value of $126,427.28. Following the completion of the transaction, the insider now directly owns 4,656 shares in the company, valued at approximately $209,706.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider David Davidson sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, July 15th. The shares were sold at an average price of $45.08, for a total transaction of $45,080.00. Following the completion of the transaction, the insider now owns 10,600 shares of the company’s stock, valued at $477,848. The disclosure for this sale can be found here. 3.50% of the stock is currently owned by insiders.
Several institutional investors have recently modified their holdings of the stock. Seven Eight Capital LLC purchased a new position in shares of Bluebird Bio during the first quarter valued at approximately $108,000. Quantbot Technologies LP boosted its position in shares of Bluebird Bio by 431.3% in the second quarter. Quantbot Technologies LP now owns 2,848 shares of the company’s stock valued at $123,000 after buying an additional 2,312 shares during the last quarter. First Mercantile Trust Co. purchased a new position in shares of Bluebird Bio during the third quarter valued at approximately $129,000. BlackRock Inc. boosted its position in shares of Bluebird Bio by 341.0% in the first quarter. BlackRock Inc. now owns 4,569 shares of the company’s stock valued at $194,000 after buying an additional 3,533 shares during the last quarter. Finally, BNP Paribas Arbitrage SA boosted its position in shares of Bluebird Bio by 110.5% in the third quarter. BNP Paribas Arbitrage SA now owns 3,084 shares of the company’s stock valued at $209,000 after buying an additional 1,619 shares during the last quarter.
About Bluebird Bio
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.